Pfizer Inc (PFE)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $164.67B
Last updated: Nov 17, 2026 at 11:06 AM ET
Pfizer Inc (PFE) Earnings: Report Dates and Results
Pfizer (PFE) is expected to report earnings on Feb 1, 2027. In the quarter ended Sep 30, 2026, Pfizer reported EPS of $0.87, above the $0.72 estimate. It beat the EPS estimate in each of the last 23 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PFE has an expected report date of Feb 1, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 4.5% above the $0.66 reported for the quarter ended Dec 31, 2025.
PFE Earnings Call
The latest PFE earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, PFE beat 37 and missed 3. Revenue for the quarter ended Sep 30, 2026 was $16.58B, down 0.4% from $16.65B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.87 | $0.72 | $0.56 - $0.83 | +20.83% | Beat | 0.0% | 19 | 1 up, 6 down | Nov 3, 2026 | $16.58B |
| Jun 30, 2026 | $0.77 | $0.68 | $0.61 - $0.76 | +13.24% | Beat | -1.3% | 20 | 3 up, 4 down | Aug 4, 2026 | $15.03B |
| Mar 31, 2026 | $0.75 | $0.72 | $0.56 - $0.81 | +4.17% | Beat | -18.5% | 20 | 7 up, 6 down | May 5, 2026 | $14.45B |
| Dec 31, 2025 | $0.66 | $0.57 | $0.44 - $0.68 | +15.79% | Beat | +4.8% | 18 | 3 up, 2 down | Feb 3, 2026 | $17.56B |
| Sep 30, 2025 | $0.87 | $0.63 | $0.57 - $0.73 | +38.10% | Beat | -17.9% | 17 | 1 up, 9 down | Nov 4, 2025 | $16.65B |
| Jun 30, 2025 | $0.78 | $0.57 | $0.47 - $0.62 | +36.84% | Beat | +30.0% | 18 | 7 up, 3 down | Aug 5, 2025 | $14.65B |
| Mar 31, 2025 | $0.92 | $0.67 | $0.59 - $0.77 | +37.31% | Beat | +12.2% | 15 | 2 up, 6 down | Apr 29, 2025 | $13.71B |
| Dec 31, 2024 | $0.63 | $0.46 | $0.34 - $0.66 | +36.96% | Beat | +530.0% | 17 | 1 up, 2 down | Feb 4, 2025 | $17.76B |
| Sep 30, 2024 | $1.06 | $0.61 | $0.30 - $0.78 | +73.77% | Beat | N/A | 15 | 7 up, 0 down | Oct 29, 2024 | $17.70B |
| Jun 30, 2024 | $0.60 | $0.46 | $0.27 - $0.59 | +30.43% | Beat | -10.4% | 15 | 6 up, 0 down | Jul 30, 2024 | $13.28B |
| Mar 31, 2024 | $0.82 | $0.51 | $0.37 - $0.82 | +60.78% | Beat | -33.3% | 16 | 5 up, 0 down | May 1, 2024 | $14.88B |
| Dec 31, 2023 | $0.10 | -$0.18 | -$0.50 - -$0.09 | +155.56% | Beat | -91.2% | 14 | 5 up, 0 down | Jan 30, 2024 | $14.57B |
| Sep 30, 2023 | -$0.17 | -$0.34 | -$0.48 - -$0.22 | +50.00% | Beat | -109.6% | 12 | 0 up, 1 down | Oct 31, 2023 | $13.49B |
| Jun 30, 2023 | $0.67 | $0.58 | $0.47 - $0.64 | +15.52% | Beat | -67.2% | 17 | 3 up, 1 down | Aug 1, 2023 | $13.01B |
| Mar 31, 2023 | $1.23 | $0.99 | $0.72 - $1.17 | +24.24% | Beat | -24.1% | 16 | 4 up, 0 down | May 2, 2023 | $18.49B |
| Dec 31, 2022 | $1.14 | $1.04 | $0.95 - $1.14 | +9.62% | Beat | +5.6% | 16 | 4 up, 1 down | Jan 31, 2023 | $25.13B |
| Sep 30, 2022 | $1.78 | $1.40 | N/A | +27.14% | Beat | +32.8% | 6 | 1 up, 1 down | Nov 1, 2022 | $22.64B |
| Jun 30, 2022 | $2.04 | $1.78 | $1.54 - $2.18 | +14.61% | Beat | +90.7% | 14 | 4 up, 2 down | Jul 28, 2022 | $27.74B |
| Mar 31, 2022 | $1.62 | $1.57 | $1.01 - $2.36 | +3.18% | Beat | +74.2% | 15 | 3 up, 2 down | May 3, 2022 | $25.66B |
| Dec 31, 2021 | $1.08 | $0.87 | N/A | +24.14% | Beat | +157.1% | 6 | N/A | Feb 8, 2022 | $23.84B |
| Sep 30, 2021 | $1.34 | $1.09 | $0.94 - $1.40 | +22.94% | Beat | +86.1% | 12 | 2 up, 0 down | Nov 2, 2021 | $24.04B |
| Jun 30, 2021 | $1.07 | $0.98 | $0.78 - $1.12 | +9.18% | Beat | +37.2% | 15 | N/A | Jul 28, 2021 | $18.90B |
| Mar 31, 2021 | $0.93 | $0.78 | $0.65 - $0.88 | +19.23% | Beat | +16.3% | 14 | N/A | May 4, 2021 | $14.52B |
| Dec 31, 2020 | $0.42 | $0.46 | $0.38 - $0.59 | -8.70% | Miss | -23.6% | 10 | N/A | Feb 2, 2021 | $11.43B |
| Sep 30, 2020 | $0.72 | $0.71 | $0.60 - $0.79 | +1.41% | Beat | -4.0% | 11 | N/A | Oct 27, 2020 | $10.28B |
| Jun 30, 2020 | $0.78 | $0.66 | $0.55 - $0.72 | +18.18% | Beat | -2.5% | 10 | N/A | Jul 28, 2020 | $9.86B |
| Mar 31, 2020 | $0.80 | $0.73 | $0.67 - $0.81 | +9.59% | Beat | -5.9% | 10 | N/A | Apr 28, 2020 | $10.08B |
| Dec 31, 2019 | $0.55 | $0.58 | $0.54 - $0.59 | -5.17% | Miss | -14.1% | 11 | N/A | Jan 28, 2020 | $1.84B |
| Sep 30, 2019 | $0.75 | $0.62 | $0.56 - $0.67 | +20.97% | Beat | -3.8% | 10 | N/A | Oct 29, 2019 | $12.68B |
| Jun 30, 2019 | $0.80 | $0.75 | $0.64 - $0.79 | +6.67% | Beat | -1.2% | 10 | N/A | Jul 29, 2019 | $13.26B |
| Mar 31, 2019 | $0.85 | $0.75 | $0.66 - $0.81 | +13.33% | Beat | +10.4% | 11 | N/A | Apr 30, 2019 | $13.12B |
| Dec 31, 2018 | $0.64 | $0.63 | $0.62 - $0.64 | +1.59% | Beat | +3.2% | 11 | N/A | Jan 29, 2019 | $1.16B |
| Sep 30, 2018 | $0.78 | $0.75 | $0.69 - $0.78 | +4.00% | Beat | +16.4% | 14 | N/A | Oct 30, 2018 | $13.30B |
| Jun 30, 2018 | $0.81 | $0.74 | $0.72 - $0.77 | +9.46% | Beat | +20.9% | 14 | N/A | Jul 31, 2018 | $13.47B |
| Mar 31, 2018 | $0.77 | $0.74 | $0.70 - $0.79 | +4.05% | Beat | +11.6% | 15 | N/A | May 1, 2018 | $12.91B |
| Dec 31, 2017 | $0.62 | $0.56 | $0.54 - $0.59 | +10.71% | Beat | +31.9% | 17 | N/A | Jan 30, 2018 | $13.70B |
| Sep 30, 2017 | $0.67 | $0.65 | $0.63 - $0.66 | +3.08% | Beat | +9.8% | 17 | N/A | Oct 31, 2017 | $13.17B |
| Jun 30, 2017 | $0.67 | $0.66 | $0.62 - $0.69 | +1.52% | Beat | +4.7% | 15 | N/A | Aug 1, 2017 | $12.90B |
| Mar 31, 2017 | $0.69 | $0.67 | N/A | +2.99% | Beat | +3.0% | N/A | N/A | May 2, 2017 | $12.78B |
| Dec 31, 2016 | $0.47 | $0.51 | N/A | -7.84% | Miss | -11.3% | N/A | N/A | Jan 31, 2017 | $13.63B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $3.23, up 3.9% from the year before. It was $2.39 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $3.23 | +3.9% |
| Dec 31, 2024 | $3.11 | +69.9% |
| Dec 31, 2023 | $1.83 | -72.2% |
| Dec 31, 2022 | $6.58 | +48.9% |
| Dec 31, 2021 | $4.42 | +62.5% |
| Dec 31, 2020 | $2.72 | -7.8% |
| Dec 31, 2019 | $2.95 | -1.7% |
| Dec 31, 2018 | $3.00 | +13.2% |
| Dec 31, 2017 | $2.65 | +10.9% |
| Dec 31, 2016 | $2.39 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,200 words across 18 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,197 | 18 | |
| 2026Q2 | Jun 30, 2026 | 7,848 | 16 | |
| 2026Q1 | Mar 31, 2026 | 6,201 | 16 | |
| 2025Q4 | Dec 31, 2025 | 9,825 | 23 | |
| 2025Q3 | Sep 30, 2025 | 7,727 | 22 | |
| 2025Q2 | Jun 30, 2025 | 9,926 | 23 | |
| 2025Q1 | Mar 31, 2025 | 3,017 | 16 | |
| 2024Q4 | Dec 31, 2024 | 9,412 | 23 |
2026Q3 Earnings Call
Opening remarks
Francesca DeMartino Chief Investor Relations Officer Good morning, and welcome to Pfizer's earnings call. I am Francesca DeMartino, Chief Investor Relations Officer. On behalf of the Pfizer team, thank you for joining us. This call is being made available via audio webcast at pfizer.com. Earlier this morning, we released our results for the third quarter of 2026 via a press release that is available on our website at pfizer.com. I am joined today by Dr. Albert Bourla, our Chairman and CEO; Cecile Guegan, our CFO; and Chris Boshoff, our Chief Scientific Officer. After their prepared remarks, we will open the call for questions. Members of our leadership team will be available for the Q&A session. Before we get started, I want to remind you that we will be making forward-looking statements and discussing certain non-GAAP financial measures. I encourage you to read the disclaimers in our slide presentation, the press release we issued this morning, and the disclosures in our SEC filings, which are all available on the IR website at pfizer.com. Forward-looking statements on the call are subject to substantial risks and uncertainties, speak only as of the call's original date, and we undertake no obligation to update or revise any of the statements. With that, I will turn the call over to Albert.
Albert Bourla Chairman and CEO Thank you, Francesca. Good morning, everyone, and thank you for joining our call. I am pleased with another strong quarter for Pfizer. Our excellent commercial execution, including 32% operational revenue growth in the quarter for our launched and acquired products, shows the underlying strength of our business. Financial discipline and ongoing productivity improvement are driving efficiency and contributing favorably to our margins. And with continued progress in our high-value R&D programs, we believe that we are on a pathway to the next stage of meaningful growth. Before going further, I want to welcome Cecile Guegan as our Chief Financial Officer. Cecile brings more than 25 years of finance leadership and the proven ability to deliver new sources of growth. She stood out in a global search for her expertise, her deep knowledge of Pfizer and our industry, and the strategic vision that I believe will help Pfizer unlock sustained long-term value for patients and shareholders. I am looking forward to Cecile's partnership, and I am confident she can help us execute with the discipline and ambition this next chapter requires. Now let me cover several highlights of our progress this quarter. Over the last few years, we have invested close to $80 billion in transactions that have equipped us with key products contributing to current commercial momentum, and platforms with transformative potential. About 80% of this investment was for Seagen, Metsera, and Biohaven.
Frequently Asked Questions About PFE
When is Pfizer's next earnings date?
Pfizer's next earnings report is expected for Feb 1, 2027.
Did PFE beat earnings estimates last quarter?
Yes. Pfizer reported EPS of $0.87 for the quarter ended Sep 30, 2026, above the $0.72 estimate, a 20.83% surprise.
What EPS do analysts expect from PFE next quarter?
The consensus EPS estimate for Pfizer for the quarter ending Dec 31, 2026 is $0.69 from 20 analysts, with estimates from $0.62 to $0.87.
How often does PFE beat earnings estimates?
Pfizer beat the EPS estimate in each of the last 23 quarters, with an average surprise of +32.33%.
PFE pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts